June 17, 2013
Stories this photo appears in:
Puma Biotechnology Inc., a biotech company based in West Los Angeles, announced March 1 it had tripled its year-over-year fourth quarter earnings to $61 million on sales of its signature breast cancer drug.
Puma Biotechnology’s flagship drug has been shown to reduce the risk of breast cancer, recurring disease or death in women who have taken it five years, according to a new study.
Puma Biotechnology has received up to $100 million in term loan funding to support the research and sale of a breast cancer drug approved this summer.
Special Report: Executive Compensation
Chief executives at small-cap companies stocked up on fatter paychecks as the markets’ recovery broadened.